Background

Anticancer drugs are notoriously characterized by a low therapeutic index, the introduction of therapeutic drug monitoring (TDM) in oncologic clinical practice could therefore be fundamental to improve treatment efficacy. In this context, an attractive technique to overcome the conventional venous sampling limits and simplify TDM application is represented by dried blood spot (DBS). Despite the significant progress made in bioanalysis exploiting DBS, there is still the need to tackle some challenges that limit the application of this technology: one of the main issues is the comparison of drug concentrations obtained from DBS with those obtained from reference matrix (e.g., plasma). In fact, the use of DBS assays to estimate plasma concentrations is highly dependent on the chemical-physical characteristics of the measured analyte, in particular on how these properties determine the drug partition in whole blood.

Methods

In the present review, we introduce a critical investigation of the DBS-to-plasma concentration conversion methods proposed in the last ten years and applied to quantitative bioanalysis of anticancer drugs in DBS matrix. To prove the concordance between DBS and plasma concentration, the results of statistical tests applied and the presence or absence of trends or biases were also considered.

中文翻译：

---

干血斑技术在抗癌药物治疗药物监测中的应用：血浆和干血斑浓度相关转换方法综述

背景

众所周知，抗癌药物的治疗指数低，因此在肿瘤临床实践中引入治疗药物监测 (TDM) 可能是提高治疗效果的基础。在这种情况下，干血斑 (DBS) 代表了一种克服传统静脉采样限制并简化 TDM 应用的有吸引力的技术。尽管在利用 DBS 进行生物分析方面取得了重大进展，但仍然需要解决一些限制该技术应用的挑战：主要问题之一是将从 DBS 获得的药物浓度与从参考基质获得的药物浓度进行比较（例如，等离子体）。事实上，使用 DBS 分析来估计血浆浓度在很大程度上取决于被测分析物的化学物理特性，

方法

在本综述中，我们介绍了对过去十年中提出的 DBS 到血浆浓度转换方法的批判性研究，这些方法应用于 DBS 基质中抗癌药物的定量生物分析。为了证明 DBS 与血浆浓度之间的一致性，还考虑了所应用的统计检验结果以及趋势或偏差的存在与否。